|Articles|March 15, 2020
Pharmacopoeia Compliance: Putting It All Together; What Is on the Horizon
Author(s)J. Mark Wiggins, Joseph A. Albanese
This final article in the series has two purposes: to summarize all the considerations that go into a company’s compendial affairs program and to look ahead at topics that will likely result in further evolution in the pharmacopoeias around the world.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
